Publication | Closed Access

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

AsthmaRheumatologyAllergyAllergy MedicinePhase 2BImmunologyPharmacotherapyVersus PlaceboEosinophilic DisorderDose-ranging StudyImmunotherapyMedicineClinical Allergy